GlassScriptPhysician profile
Elizabeth Silva Baeza
NPI 1568907368
$1,552.40
in general payments reported to CMS, 2019-2025
25 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $378 · 2024: $552 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $184.05 | 2024-2025 | Doc Band |
| Pfizer INC. | $159.77 | 2022-2025 | |
| Sanofi Pasteur INC. | $114.37 | 2022-2023 | |
| Exact Sciences Corporation | $101.44 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $96.93 | 2024-2025 | Airsupra |
| Collegium Pharmaceutical, INC. | $91.16 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $91.06 | 2024 | |
| Merck Sharp & Dohme LLC | $90.87 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Alk-Abello, INC | $73.71 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Hologic Sales and Service, LLC | $67.47 | 2023-2024 | Aptima |
| Globus Medical, INC. | $64.40 | 2025 | Senza |
| Amgen INC. | $51.85 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $42.25 | 2022-2025 | Arexvy, Shingrix |
| Dexcom, INC. | $40.63 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $36.93 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $35.35 | 2022-2024 | Senza |
| Abbvie INC. | $31.70 | 2024 | |
| Corium, LLC | $29.61 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $29.46 | 2023 | Qelbree |
| Dynavax Technologies Corporation | $24.78 | 2023 | Heplisav-B |
| Ultragenyx Pharmaceutical INC. | $22.84 | 2024 | Crysvita |
| Novo Nordisk INC | $21.96 | 2022 | |
| Seqirus USA INC | $17.63 | 2024 | Flucelvax, Fluad |
| Lnhc, INC | $16.66 | 2025 | Zelsuvmi |
| Neos Therapeutics, LP | $15.52 | 2024 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Silva Baeza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.